eShowcase: VISTA
Shorter Study Start-Up Times Targeted with Site Assessment Process Tool
Shorter Study Start-Up Times Targeted with Site Assessment Process Tool
Scientific Software Tools (Media, PA) has released the latest version of VISTA, its Web-based automated site technology assessment service. The new service incorporates additional features to assess for e-clinical studies.
VISTA allows qualitative surveys conducted by the investigative site-—including the technology survey—to be completed online, which eliminates paper-based surveys and manual entry into a database. Also, this Web-based process allows investigators a single point of contact for all required surveys.
VISTA presents the data obtained from the surveys and the technical assessment in XML format, which allows for easier data sharing into databases, as well as improved data sharing between different systems used by all parties involved, including clinical staff, investigators, sponsors, and others.
VISTA Plus includes additional data capture and reporting, and VISTA Services includes additional components to the basic service.
Scientific Software Tools, Inc., (610) 891-1640, www.vistasurveys.com
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
